Principal Investigators

    Hayden, Michael R


    University of British Columbia

    Contact information of lead PI



    Title of project or programme

    Novel approaches to modulate key targets in the pathogenesis of Huntington Disease

    Source of funding information


    Total sum awarded (Euro)

    € 528,267

    Start date of award


    Total duration of award in years


    The project/programme is most relevant to:

    Huntington's disease


    Research Abstract

    Huntington disease (HD) is a progressive neurodegenerative disease with no way to alter the course of the illness. The underlying genetic defect is a trinucleotide expansion in the huntingtin (htt) gene. A promising therapeutic approach for HD is to selectively prevent the expression of mutant htt. We will use antisense oligonucleotides (ASOs) to test this approach in mouse models, targeting single nucleotide polymorphisms that are only present on the mutant and not the wild-type htt gene. Additionally, cleavage of mutant htt by caspase-6, phosphorylation and excitotoxicity are implicated as crucial factors in the pathogenesis of HD. In order to further validate caspase-6 as a therapeutic target, we will ablate caspase-6 expression and test the impact on the phenotype in an HD mouse model. Methods to increase phosphorylation will also be assessed as to their impact on phenotypic features of HD. We will furthermore investigate factors that lead to the activation of caspase-6 and thus represent additional targets for therapy development. In the excitotoxic pathway, we have identified the aberrant localization of NR2B receptors as a pathogenic mechanism, and we will modulate this mislocalization through genetic and therapeutic trials in an HD mouse model. Additionally, we will test compounds that modulate the signalling pathway downstream of NR2B receptors to ameliorate excitotoxicity. The basis of this proposal is to validate novel therapeutic approaches for the treatment of HD in vivo. The end result is to provide essential information for therapeutic strategies and evaluate compounds which prevent and/or ameliorate the disease.

    Lay Summary

    Further information available at:

Types: Investments > €500k
Member States: Canada
Diseases: Huntington's disease
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF